Nivolumab Plus Chemotherapy Prolongs Survival in Advanced Gastric Cancer

Markus Moehler, MD, PhD, discusses the survival outcomes of nivolumab in combination with chemotherapy in patients with advanced gastric cancer.

Markus Moehler, MD, PhD, the head of Gastrointestinal Oncology at Mainz University Clinic, discusses the survival outcomes of nivolumab (Opdivo) in combination with chemotherapy in patients with advanced gastric cancer.

In the CHECKMATE-649 study (NCT02872116), overall survival (OS) and progression-free survival (PFS) were improved with nivolumab/chemotherapy compared with chemotherapy alone in patients with advanced gastric cancer. In the primary population, where patients had a PD-L1 tumor proportion score of 5 or higher, the median OS improved from 11.1 to 14.4 months, according to Moehler.

Additionally, OS for all randomized patients proved significant. In the PD-L1-postive group, PFS benchmarks were highly met. Additionally, the 1-year survival rate increased from 46% to 57% with the combination.